AITbiotech Exhibits abTES Molecular Diagnostics Assays at MEDLAB 2017

AITbiotech Pte Ltd., a Singapore-based genomic service and molecular diagnostics (MDx) company, exhibited its comprehensive range of abTES MDx assays, including its newly launched Zika assays and the multiplex respiratory panel, at MEDLAB 2017, the world’s largest laboratory exhibition and congress in the Middle East.

AITbiotech provides a complete suite of genomic services, including capillary sequencing, next-generation sequencing services, bioinformatics services and customized molecular services, to the research, healthcare and biomedical industries in Singapore and Asia. The company also manufactures and distributes its own line of real-time PCR pathogen detection assays branded as abTES in the Asian and European markets.

At MEDLAB 2017, held at the Dubai International Convention & Exhibition Centre, UAE, from February 6-9, 2017, AITbiotech showcased its abTES MDx range of assays, which uses real-time PCR (qPCR) technology to offer unsurpassed sensitivity and specificity, thus allowing for accurate detection of pathogens within hours. AITbiotech’s assays with internal control for simultaneous detection and differentiation of infectious pathogens are compatible with various platforms. Its timesaving and user-oriented protocols ensure fast turnaround time, from sample to results in 3.5 hours.

Alex Thian, CEO of AITbiotech, said, “We are excited to be part of this premier exhibition. After many years of development of our assays and focusing in the Asia Pacific market, we are finally are able to expand to more markets. We believe that Middle East will be the best market for us to expand into, primarily due to the relevance of our abTES assay offerings to the needs of the Middle East Market. We are looking for local partners to work with us collaboratively to introduce our abTES MDx assays to the Middle East market.”